Compare Centrus Energy Corp (LEU) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centrus Energy Corp vs Repligen Corporation Common Stock — how do they compare? Centrus Energy Corp trades at $116.35 (market cap $2.45B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 4.6× Centrus Energy Corp's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Centrus Energy Corp for 31 Days and Repligen Corporation Common Stock for 0 Days on average.
| LEU | RGEN | |
|---|---|---|
Market Cap | $2.45B | $11.31B |
Volume | 1,447,414 | 1,216,919 |
Sector | Energy | Health |
52-Week High | $436.00 | $194.57 |
52-Week Low | $119.95 | $102.87 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $1.76B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $134.28, down 0.76% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows elevated valuation metrics with a P/E of 63.47 and P/S of 5.64, while profitability metrics remain solid with a 10.23% net income margin. Recent news highlights Centrus' strategic positioning as the only US-licensed producer of high-assay low-enriched uranium (HALEU), with multiple new supply contracts announced in September 2026.
The investment case hinges on execution of nuclear fuel contracts amid growing demand, but faces risks from high valuation and operational challenges. Analyst consensus remains positive with a $218.10 price target, though technical indicators suggest near-term pressure. The company's unique position in the nuclear supply chain offers growth potential, but requires careful monitoring of cash flow trends and contract execution.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
